Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

340B Drug Allocation Provision In Tax Bill Needs Clarification, Attorney Says

Executive Summary

A provision in a tax bill passed by the House May 28 would require manufacturers facing a shortage of an inpatient drug used by 340B program hospitals to submit a drug allocation plan to HHS for approval

You may also be interested in...



Inpatient Drug Discounts For 340B Providers Resurface In Jobs Bill

Dropped from health reform, a proposal to extend 340B discounts to inpatient drugs is included in "The American Jobs and Closing Tax Loopholes Act," sponsored by Senate and House committee chairmen.

“Penny Pricing” Guidance Document On Hold Until 340B Office Gets Funding

A long-promised official policy on "penny pricing" for drugs sold to 340B entities is on hold until Congress appropriates funding for the Health Resources and Services Administration's Office of Pharmacy Affairs. Until then, drug manufacturers will need to work on a case-by-case basis with OPA to resolve any pricing issues

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052266

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel